Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus standard chemotherapy in children with newly diagnosed FLT3-mutated acute myeloid leukemia
2023-509834-20-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoints: Safety and Tolerability. Planned start Mar 2019; status: authorised.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-509834-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509834-20-00.